Welcome to our dedicated page for Nutex Health SEC filings (Ticker: NUTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nutex Health Inc. (NUTX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Nutex Health is a Houston-based, physician-led healthcare management and operations company with a Hospital Division and a Population Health Management Division, and its filings explain how these segments are reflected in its financial statements and risk disclosures.
Through annual reports on Form 10-K and quarterly reports on Form 10-Q, Nutex Health presents consolidated financial statements, segment revenue for its hospital and population health management divisions, details on operating costs, noncontrolling interests and non-GAAP metrics such as EBITDA and Adjusted EBITDA. Recent filings also describe restatements of prior financial statements, including reclassification of non-cash stock-based compensation obligations related to under-construction and ramping hospitals, and explain that these adjustments were non-cash and did not materially affect key metrics such as revenue, liquidity, operating cash flow, Adjusted EBITDA or patient visits for the periods presented.
Current reports on Form 8-K document material events such as the release of quarterly and annual earnings, notices from Nasdaq regarding timely filing requirements and subsequent confirmation of regained compliance, appointment of senior executives, authorization of stock repurchase programs and disclosure of litigation, including a derivative action filed in federal court. These 8-K filings help investors understand significant developments between periodic reports.
On Stock Titan, Nutex Health filings are updated in near real time from EDGAR and are accompanied by AI-powered summaries that highlight key points from lengthy documents. Users can quickly see where Nutex Health discusses topics such as arbitration-related revenue through the Independent Dispute Resolution (IDR) process, capital structure, stock-based compensation, and legal or regulatory matters. The filings page also surfaces ownership and transaction data from forms such as Form 4, enabling readers to review insider transactions alongside the company’s broader financial and operational disclosures.
Nutex Health Inc. reported that Chief Operating Officer Wesley Shane Bamburg acquired 2,411 restricted stock units (RSUs) on March 11, 2026 as equity compensation. Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029, aligning Bamburg’s incentives with the company’s long-term performance rather than reflecting any open-market share purchase or sale.
Nutex Health Inc. director and president Warren Hosseinion reported two equity-related moves. On March 19, 2026 he made an open-market purchase of 252 shares of common stock at a price of $94.0723 per share, bringing his direct common stock holdings to 7,765 shares.
On March 10, 2026 he also exercised 3,656 restricted stock units into an equivalent number of common shares, a derivative exercise recorded at a conversion price of $0.00 per unit, with 12,465 restricted stock units beneficially owned following that grant. A footnote explains this Form 4 corrects the previously reported RSU balance from an earlier filing for that March 10 transaction.
Nutex Health Inc. director Frank E. Jaumot bought 150 shares of common stock in an open-market purchase. The transaction took place on March 20, 2026 at a price of $93.555 per share. After this trade, he directly holds 150 Nutex Health shares.
Nutex Health director Kelvin Spears reported a small open-market share purchase and an RSU-related stock acquisition. The filing also corrects his previously reported RSU holdings.
On March 17, 2026 he bought 10 common shares at $94.46, bringing his direct stake to 32,137 shares. A March 10, 2026 derivative transaction converted 116 restricted stock units into common stock, and 339 RSUs are now reported as beneficially owned following the correction.
Nutex Health Inc. Chief Legal Officer-Healthcare Pamela W. Montgomery reported acquiring additional equity in the company. She made an open-market purchase of 79 shares of common stock at a price of $88.8699 per share, bringing her directly held common stock position to 2,758 shares.
She also exercised a derivative position in the form of 1,523 restricted stock units, converting them into an equivalent common stock interest at a stated exercise price of $0.00, with 4,441 restricted stock units beneficially owned following this transaction. A footnote explains that this filing corrects the previously reported number of restricted stock units from an earlier Form 4 relating to the March 10, 2026 RSU grant.
Nutex Health Inc. is asking stockholders to vote at its 2026 Annual Meeting, held virtually on April 23, 2026, on three main items. Stockholders are asked to re-elect seven directors for one-year terms, including CEO Thomas Vo and President Warren Hosseinion.
They are also asked to give an advisory “say-on-pay” vote on executive compensation and to ratify Grant Thornton LLP as independent auditor for the year ending December 31, 2026. The meeting will be conducted exclusively online, and only holders of the 5,628,591 shares of common stock outstanding as of February 27, 2026 may vote.
Stockholders can vote in advance by Internet, telephone, or mail, or during the virtual meeting using a control number. The proxy also describes Nutex’s board committees, director independence, compensation program, and prior disclosure of internal control weaknesses and audit firm changes.
Nutex Health Inc. Chief Legal Officer Luqman Elisa V reported routine equity compensation activity involving restricted stock units and common stock. Restricted stock units convert into common stock on a one-for-one basis, and the officer held 4,441 such units following the reported transaction.
Subsequent to vesting, 2,084 common shares were issued, of which 784 shares were delivered to satisfy tax withholding obligations, leaving the remainder as net shares. After these movements, the officer beneficially owned 2,370 common shares, including 2,360 shares held directly and 10 shares held indirectly through a spouse.
Nutex Health Inc. Chief Legal Officer-Healthcare Pamela W. Montgomery reported routine equity compensation activity. She exercised restricted stock units that convert into common stock on a one-for-one basis, resulting in the issuance of 2,084 shares of common stock, of which 776 shares were delivered to cover tax withholding obligations.
After these transactions, Montgomery directly held 2,679 shares of common stock. She was also granted 1,525 restricted stock units on March 11, 2026, scheduled to vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029.
Nutex Health Inc. director Kelvin Spears reported compensation-related stock activity. He received 183 shares of common stock upon vesting of previously granted restricted stock units, with 82 of those shares withheld to cover tax obligations, leaving a net 101 new shares and bringing his direct common stock holdings to 32,127 shares.
He was also granted 116 new restricted stock units that each convert into one share of common stock and are scheduled to vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029. These transactions are routine equity compensation events rather than open-market purchases or sales.
Nutex Health Inc. Chief Medical Officer Michael L. Chang reported equity compensation and related tax withholding transactions. On March 10, 2026, he was granted 1,936 restricted stock units (RSUs), which will vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029. A related entry shows 2,084 common shares issued subsequent to vesting, with 769 shares delivered to cover tax withholding obligations at an indicated value of $86.2224 per share, a non‑market disposition that does not represent an open‑market sale. Following these transactions, Michael Chang PLLC directly holds 82,356 common shares, and Dr. Chang directly owns an additional 984 shares, reflecting ongoing equity alignment through both direct and indirect holdings.